AGENDA
All times listed are in EST

Monday, February 22

11:00am-1:00pm  Scientific Session 1: Novel influences on tumorigenesis and progression
Each talk will be followed by Live Q&A
Chair: A. Hunter Shain, University of California, San Francisco

11:00-11:10 Opening Remarks

11:10-11:45  Keynote Lecture
William Kaelin, Jr., Professor of Medicine, Dana-Farber Cancer Institute
(Re)emerging principles of cancer therapy

11:45-12:10 Hilary Coller, Professor, Molecular, Cell and Developmental Biology, University of California, Los Angeles
Autophagy in the melanoma microenvironment

12:10-12:35 David Lombard, Associate Professor of Pathology, University of Michigan
Oncogenic role of the SIRT5 deacylase in melanoma

12:35-1:00 Titia de Lange, Leon Hess Professor, The Rockefeller University
Marcin Imielinski, Assistant Professor, Weill Cornell Medical School – Q&A only
The role of telomere crisis in acral melanoma

5:30-6:30pm  Young Investigator Social Hour (by invitation only)

6:30-7:30pm  Poster Session 1

Tuesday, February 23

9:30-10:30am  Poster Session 2

11:00am-1:00pm  Scientific Session 2: Novel immunotherapy targets and mechanisms of immune-related adverse events
Each talk will be followed by Live Q&A
Chair: Stefani Spranger, MIT

11:00-11:05 Opening Remarks

11:05-11:40  Keynote Lecture:
Jennifer Wargo, Professor, University of Texas MD Anderson Cancer Center
Understanding responses to cancer therapy: The tissue is the issue, the scoop is in the poop, and you are what you eat
11:40-12:05  Pan Zheng, Professor of Surgery, University of Maryland, Baltimore  
*CTLA-4 lysosomal degradation governs the immune-related adverse events in anti-CTLA4 antibody immunotherapy*

12:05-12:30  John Wilson, Assistant Professor, Vanderbilt University  
*Engineering smart technologies for immuno-oncology*

12:30-12:55  Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute  
*Molecular pathways of colon inflammation induced by cancer immunotherapy*

5:30-6:30pm  Patient Advocate Social Hour – Sponsored by Mollie’s Fund *(by invitation only)*

6:30-7:30pm  Networking Roundtables Session 1

Wednesday, February 24

9:30-10:30am  Networking Roundtables Session 2

11:00-1:00pm  Scientific Session 3: New approaches to detecting and treating melanoma  
Each talk will be followed by Live Q&A  
*Chair: Ku-Lung (Ken) Hsu, University of Virginia*

11:00-11:05  Opening Remarks

11:05-11:40  **Keynote Lecture:**  
Richard Marais, Director, Cancer Research UK Manchester Institute  
*Genetic approaches to refining melanoma treatment*

11:40-12:05  Keiran Smalley, Director, The Melanoma and Skin Cancers Center of Excellence, Moffitt Cancer Center  
*Multi-omics approaches to define the landscape of acral melanoma*

12:05-12:30  Liz Patton, Programme Leader MRC Human Genetics Unit, University of Edinburgh  
*Transcriptional mechanisms that underlie developmental cell states in melanoma*

12:30-12:55  Allan Halpern, Chief, Dermatology Service, Memorial Sloan Kettering Cancer Center  
*Advances and controversies in the early detection of melanoma*

1:30-2:30pm  **Moderated Panel Discussion – No patient left behind: Impact of the pandemic and new directions for clinical research in rare melanomas.**  
*Panelists:* Maryam Asgari, Massachusetts General Hospital; Steven Lemery, US Food and Drug Administration; Ned Sharpless, National Cancer Institute.  
**Moderator:** Elliott Sigal, MRA Board of Directors